Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination ophthalmic solution containing three active ingredients—cyclopentolate, tropicamide, and phenylephrine—used primarily for rapid and effective pupillary dilation (mydriasis) during eye examinations or procedures. Cyclopentolate and tropicamide are antimuscarinic agents that block muscarinic acetylcholine receptors in the eye, leading to relaxation of the sphincter muscle of the iris (causing mydriasis) and paralysis of accommodation (cycloplegia). Phenylephrine is an alpha-1 adrenergic receptor agonist that stimulates contraction of the dilator muscle of the iris, further enhancing pupil dilation. The combination provides both strong mydriatic effect and moderate cycloplegic action. It is typically used in clinical settings for diagnostic purposes or preoperative preparation[1][2][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclopentolate + tropicamide + phenylephrine.